Physician profile
Jacquelyn A Smith
NPI 1154769131
$62,811.64
in general payments reported to CMS, 2019-2025
32 companies · $10K in 2025
The $10K reported for 2025 was more than what 90% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,639 · 2020: $12K · 2021: $9,636 · 2022: $9,131 · 2023: $11K · 2024: $4,414 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,088 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,640 · Consulting Fee: $5,575 · Travel and Lodging: $2,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,088.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,640.00 |
| Consulting Fee | $5,575.00 |
| Travel and Lodging | $2,221.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $46,642.53 | 2019-2025 | Ofev, Cyltezo |
| Janssen Biotech, INC. | $2,873.36 | 2019-2025 | Tremfya, Remicade, Stelara |
| Horizon Therapeutics Plc | $2,242.16 | 2019-2023 | Krystexxa |
| Amgen INC. | $2,226.92 | 2019-2025 | Enbrel, Krystexxa, Otezla |
| Abbvie INC. | $2,202.39 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,304.58 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,015.32 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $580.91 | 2020-2025 | Acthar |
| Pfizer INC. | $530.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $502.36 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $479.41 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $362.98 | 2020-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $215.33 | 2019-2024 | Taltz |
| Alexion Pharmaceuticals, INC. | $211.28 | 2022-2025 | Strensiq |
| Genzyme Corporation | $190.54 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $152.77 | 2023-2025 | Lupkynis |
| Radius Health, INC. | $139.99 | 2021-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $123.26 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $115.59 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $111.24 | 2022 | |
| Celgene Corporation | $110.59 | 2019-2021 | |
| Sobi, INC | $109.34 | 2020-2025 | |
| Genentech USA, INC. | $103.10 | 2023-2025 | Actemra, Gazyva |
| Organon LLC | $67.03 | 2023-2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $33.25 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $33.12 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.55 | 2025 | Uptravi |
| United Therapeutics Corporation | $26.98 | 2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $24.58 | 2019-2020 | |
| Antares Pharma, INC. | $17.69 | 2020 | |
| Pacira Therapeutics, INC. | $16.98 | 2020 | |
| Ferring Pharmaceuticals INC. | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.